PFE: Pfizer to Pay $325M Fine for Illegal Marketing

Drugmaker Pfizer (PFE) has agreed to pay a $325 million to insurers and other healthcare benefit providers for falsely marketing its drug Neurontin. More 

When Fraud Bites Business: Lost Fortunes, Reputations and Lives

Credit card breaches, swindlers and even baby formula form a web of business-targeted fraud that spans the globe. More 

Top 10 Dow Dividend Stocks for May

In a low-yield environment, attractive blue-chips look even more appealing. Here are the top 10 Dow Dividend stocks for May. More 

Nexium OTC: Popular Pill Now Available Without Prescription

A nonprescription version of the popular heartburn drug Nexium was jut released by Pfizer and it's significantly cheaper than Nexium. More 

5 Stocks to Sell in June

The market is making record highs, but these names sure aren't. Weak technicals suggest plenty more downside to come, which makes them stocks to sell. More 

Is AstraZeneca a Buy After Pfizer Breakup? 3 Pros, 3 Cons

AZN turned down Pfizer's offer -- a premium of more than 40% for AZN stock -- sending shares down more than 10%. But is that actually a buying opportunity? More 

AZN, PFE: AstraZeneca Rejects ‘Final’ Pfizer Bid

AstraZeneca (AZN) has rejected another bid from Pfizer (PFE) -- a reported $119 billion improved takeover offer. More